PCSK9 and Hypercholesterolemia: Alirocumab (formerly REGN727/SAR236553; Sanofi-Regeneron) is a fully human, monoclonal antibody targeted to PCSK9 currently in Phase 3 development for the treatment of hypercholesterolemia.